Scarica l'app Stockscreener
21.33
1.72%
0.38
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RARE Giù?
Forum
Previsione
Frazionamento azionario
Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Ultragenyx (RARE) Shares Positive Results From DTX301 Phase 3 Study - Yahoo Finance
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action ... - Caledonian Record
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
Ultragenyx Pharmaceutical Reports FDA Acceptance of IND Application for UX016 - Bitget
Ultragenyx Pharmaceutical (NASDAQ:RARE) Trading Up 8.7%Still a Buy? - MarketBeat
RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securitie - GuruFocus
Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND - Yahoo Finance
Holzer & Holzer, LLC Reminds Investors of April 6, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Mereo BioPharma Group plc (MREO), POMDOCTOR LIMITED (POM), and Ultragenyx Pharmaceutical Inc. (RARE) - lincolnjournal.com
RARE Deadline: RARE Investors with Losses in Excess of $100K Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - The Malaysian Reserve
Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors - globenewswire.com
Patient-Funded UX016 IND Clearance Might Change The Case For Investing In Ultragenyx Pharmaceutical (RARE) - Yahoo Finance
Ultragenyx Stock Gaps Down 5% Amid Weak Start and Market Concerns - Markets Mojo
Ultragenyx (RARE) Gains FDA Clearance for New Drug UX016 - GuruFocus
Investors in Ultragenyx Pharmaceutical Inc. Should Contact - globenewswire.com
POM IMPORTANT DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages PomDoctor Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action - GlobeNewswire Inc.
RARE FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ultragenyx Pharmaceutical ... - Caledonian Record
RARE FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - GlobeNewswire Inc.
NASDAQ: RARE CLASS ACTION NOTICE - marketscreener.com
Ultragenyx gains FDA IND clearance of UX016 for GNE myopathy - MSN
Ultragenyx Investors Urged to Join Securities Fraud Lawsuit - National Today
Ultragenyx Wins FDA IND Clearance for UX016 Therapy - TipRanks
Ultragenyx Announces FDA Clearance of IND for UX016 to Treat GNE Myopathy - Minichart
Ultragenyx Pharmaceutical Inc. Announces FDA Clearance Of Investigational New Drug Application For Ux016, A Sialic Acid Prodrug For The Treatment Of GNE Myopathy - marketscreener.com
Ultragenyx (RARE) wins FDA IND clearance, plans UX016 Phase 1/2 GNE myopathy trial - Stock Titan
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy - The Manila Times
Rare muscle disease with no approved drugs gets a new trial - Stock Titan
Ultragenyx downgraded to neutral at Goldman Sachs on setrusumab data - MSN
Assenagon Asset Management S.A. Has $4.59 Million Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Securities Class Action LawsuitRGRD Law - The Daily Tribune News
RARE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Investors of Securities Class Action Deadline on April 6, 2026 - PR Newswire
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Q4 2025 earnings call transcript - MSN
Is It Time To Reconsider Ultragenyx Pharmaceutical (RARE) After Its Prolonged Share Price Slump? - Sahm
[ARS] Ultragenyx Pharmaceutical Inc. SEC Filing - Stock Titan
Ultragenyx (NASDAQ: RARE) seeks approval for 2026 equity plan and director slate - Stock Titan
ULTRAGENYX DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical ... - Caledonian Record
ULTRAGENYX DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, - GlobeNewswire
Vanguard disaggregates Ultragenyx holdings (NASDAQ: RARE) after realignment - Stock Titan
RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. - GlobeNewswire
2026-03-27 | RARE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:RARE | Press Release - Stockhouse
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire
RARE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), TELA Bio (TELA) and Nuvalent (NUVL) - The Globe and Mail
Ultragenyx Pharmaceutical (NASDAQ:RARE) Upgraded to "Strong-Buy" at Truist Financial - MarketBeat
RARE Deadline: RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - Lelezard
Ultragenyx Pharmaceutical Stock Hits Day Low of $18.29 Amid Price Pressure - Markets Mojo
Ultragenyx Pharmaceutical Hits Day Low at $19.86 Amid Price Pressure - Markets Mojo
Ultragenyx Pharmaceutical Hits 52-Week Low at $18.29 Amidst Declining Performance - Markets Mojo
Lost Money on Ultragenyx Pharmaceutical Inc.(RARE)? Join Class A - GuruFocus
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors - globenewswire.com
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.
RARE Investor Alert: Ultragenyx Pharmaceutical Inc. Stockholders with Large Losses Should Contact Ro - PharmiWeb.com
Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ: - GlobeNewswire
RARE Investor Alert: Ultragenyx Pharmaceutical Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit - The AI Journal
FinancialContentRARE Investor Alert: Ultragenyx Pharmaceutical Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit - FinancialContent
Ultragenyx Nears Key Inflection Point With Completed Phase 3 Gene Therapy Study in GSDIa - TipRanks
Lost Money on Ultragenyx Pharmaceutical Inc.(RARE)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - PR Newswire
RARE Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Ultragenyx Pharmaceutical Inc. Securities Lawsuit -- The Gross Law Firm - Sahm
Momentum Shift: Will Ultragenyx Pharmaceutical Inc outperform tech stocksGold Moves & Free Community Supported Trade Ideas - baoquankhu1.vn
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):